Litcius/Paper detail

Is hydroxychloroquine beneficial for COVID-19 patients?

Xing Li, Ying Wang, Patrizia Agostinis, Arnold B. Rabson, Gerry Melino, Ernesto Carafoli, Yufang Shi, Erwei Sun

2020Cell Death and Disease114 citationsDOIOpen Access PDF

Abstract

Abstract The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world 1–3 , the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 2020 4 . The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir 5 , to control the disease and halt the pandemic.

Topics & Concepts

HydroxychloroquineOutbreakPandemicCoronavirus disease 2019 (COVID-19)CoronavirusMedicinePublic healthSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDiseaseIntensive care medicineVirologyInfectious disease (medical specialty)Internal medicinePathologyCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Infectious Encephalopathies and Encephalitis